Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum

Craig Hallum initiated coverage on shares of Actuate Therapeutics (NASDAQ:ACTU) in a research note published on Tuesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $21.00 target price on the stock.

Separately, HC Wainwright initiated coverage on shares of Actuate Therapeutics in a research note on Monday, March 17th. They issued a “buy” rating and a $20.00 price objective for the company.

Actuate Therapeutics Stock Up 1.8 %

Shares of ACTU stock opened at $8.52 on Tuesday. Actuate Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $11.73. The stock’s 50-day moving average is $7.39 and its two-hundred day moving average is $8.05.

Hedge Funds Weigh In On Actuate Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. OMERS ADMINISTRATION Corp bought a new stake in shares of Actuate Therapeutics during the 4th quarter worth $84,000. Mercer Global Advisors Inc. ADV bought a new stake in Actuate Therapeutics during the fourth quarter valued at about $130,000. Voss Capital LP bought a new stake in Actuate Therapeutics during the fourth quarter valued at about $440,000. Envestnet Asset Management Inc. acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at about $83,000. Finally, BIOS Capital Management LP bought a new position in shares of Actuate Therapeutics in the fourth quarter worth about $78,753,000.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.